Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xu Ling

Showing results (101-110 of 101) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 101 results.
The Lancet. Diabetes & Endocrinology|November 3, 2019
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, et al.
Pageof 11

Showing results (101-110 of 101) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 101 results.
The Lancet. Diabetes & Endocrinology|November 3, 2019
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, et al.
Pageof 11